A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in subjects with prostate cancer and cardiovascular disease.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02663908.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationFerring Pharmaceuticals Inc

• Primary ID000108
• Secondary IDsNCI-2018-00135
• ClinicalTrials.gov IDNCT02663908